What is the right balance between equity, royalties, collaborative research income for the academic institutions in the process of spinning out companies?
Caroline is CEO and co-founder of the next generation therapeutic biologics company, Elasmogen. The company discovers and develops soloMERs which are novel drugs for site-specific treatment of auto-immune inflammatory diseases and cancer. Before establishing Elasmogen, she successfully led teams at Wyeth Inc and subsequently Pfizer Inc in Global Bio-therapeutic Technologies progressing early platform technologies to late stage clinical development. Prior to this she was Alliance and Programs Manager at Haptogen Ltd and a key part of the acquisition team that successfully exited the business to Wyeth Inc. She has been awarded a prestigious Royal Society of Edinburgh Enterprise Fellowship, named in the top 20 female biotech CEOs in Europe in 2017, is a doctoral graduate from the University of Aberdeen in Biochemistry and a master graduate in business (MBA) from Robert Gordon’s University.